Dreyling Martin
Medizinische Klinik III, Klinikum der Universität München-Campus Großhadern, München.
Ther Umsch. 2010 Oct;67(10):511-6. doi: 10.1024/0040-5930/a000087.
Follicular lymphoma (FL) represent the majority of indolent lymphoma in daily practice. The vast majority of patients present in advanced stage (Ann Arbor) III/IV. At first diagnosis painless palpable lymph nodes as well as B-symptoms and less frequently bone marrow infiltration with impairment of the normal hematopoiesis or hypersplenism are observed. The clinical course is usually characterized by only slowly progressive disease but constant relapses. During the last 10 years the clinical outcome especially in advanced stages has been remarkably improved by the introduction of antibody-based strategies (combined immuno-chemotherapy, rituximab maintenance, radioimmunotherapy) as well as optimized transplantation strategies (myeloablative high dose therapy, allogeneic transplantation with dose-reduced conditioning). Accordingly, current series report on an improved median overall survival of 15-20 years.
在日常临床实践中,滤泡性淋巴瘤(FL)占惰性淋巴瘤的大多数。绝大多数患者初诊时处于晚期(Ann Arbor分期III/IV期)。初诊时可观察到无痛性可触及淋巴结、B症状,较少见的是骨髓浸润伴正常造血功能受损或脾功能亢进。临床病程通常仅表现为疾病进展缓慢但复发频繁。在过去10年中,通过引入基于抗体的治疗策略(联合免疫化疗、利妥昔单抗维持治疗、放射免疫治疗)以及优化的移植策略(清髓性高剂量治疗、减低预处理剂量的异基因移植),临床结局尤其是晚期患者的结局有了显著改善。因此,目前的系列报道显示中位总生存期提高至15 - 20年。